Spark Therapeutics

Spark Therapeutics is developing potentially curative, one-time gene therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases.  The founding team includes scientists who have led the advancement of gene therapy over the past two decades, establishing human proof of concept of the expression of gene therapy in the eye and liver.  Spark’s robust pipeline includes SPK-RPE65, a fully enrolled, pivotal Phase 3 program in blindness due to mutations in the RPE65 gene, SPK-CHM for the treatment of choroideremia, and SPK-FIX, a program for the potential treatment of hemophilia B through a global collaboration with Pfizer Inc., as well as preclinical programs to address neurodegenerative diseases and other retinal degenerative diseases and hematologic disorders.  Spark has rights to a proprietary manufacturing platform that has a track record supporting clinical studies across diverse therapeutic areas and routes of administration.  Spark’s expertise across research, clinical, regulatory and manufacturing builds on a legacy of innovation and excellence in gene therapy established by Spark’s team while at The Children’s Hospital of Philadelphia Center for Cellular and Molecular Therapeutics.

Roche Holding AG

PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Cynthia Pussinen as chief technical officer (CTO). Cynthia has more than 25 years of experience in the biopharma industry, leading teams in manufacturing, quality, supply chain, formulation development and process sciences. As CTO, she will oversee Spark's manufacturing and technical operations, including pipeline process development, preclinical and clinical manufacturing, and the commercial manufacturing and distribution of LUXTURNA® (voretigene neparvovec-rzyl).

Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer

First participant dosed in the RESOLUTE SM trial, a Phase 1/2 dose-escalation study of SPK-3006

Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease

Mario Gabelli (Trades, Portfolio)’s firm GAMCO Investors sold shares of the following stocks during the fourth quarter of 2019.

GAMCO Investors Exits Viacom, Spark Therapeutics

Roche Holding (OTCQX: RHHBY) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc.

Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition

Swiss drugmaker Roche  plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics  on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.

Roche to complete $4.3 billion Spark deal as regulators give all clear

Swiss drugmaker Roche  has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics , the Federal Trade Commission said on Monday, clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A.

U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics

ArQule

Merck

Sanofi

Synthorx Inc

Week Begins with Biotech Mergers

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

ACADIA Pharma

Arrowhead Pharmaceuticals

China Biologic Products Holdings

Galapagos

Natera

Zai Lab Ltd.

Many of these biotech companies are beating the Nasdaq Biotech Index. With cutting-edge therapies, these are great names to buy.

7 Exciting Biotech Stocks to Buy Now

Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Spark Therapeutics (ONCE) Report Negative Q3 Earnings? What You Should Know

Roche's acquisition of Spark will likely close before year's end, an analyst said after reports suggested U.S. regulators would bless the deal.

Why Roche's Acquisition Of Spark May Be Complete By Year's End

PHILADELPHIA, Oct.  25, 2019  (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Award for Best Biotechnology Product to LUXTURNA® (voretigene neparvovec-rzyl). The award, announced at the Prix Galien USA Awards Ceremony on Oct. 24, 2019 at the American Museum of Natural History in New York City, recognizes the development of the world’s most innovative medicines that help improve the overall human condition.

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

The Federal Trade Commission staff reviewing Roche's  plan to buy U.S.-based gene therapy specialist Spark Therapeutics  for $4.3 billion recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday.

FTC staff recommends approval of Roche deal for Spark: report

uniQure

Shares of gene therapy biotech companies launched in high volume in afternoon action Thursday on rumors the U.S. Federal Trade Commission cleared Roche's takeover of Spark Therapeutics.

Gene Therapy Stocks Rocket On Rumor Roche Clinched Its Spark Buyout

Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD

Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing

Roche's (RHHBY) acquisition of Spark Therapeutics gets delayed once again to allow the FTC more time for review.

Roche Extends Offer to Acquire Spark Therapeutics Yet Again

Roche Holding  and Spark Therapeutics  announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark again extend $4.3 billion takeover offer

PHILADELPHIA, Aug.  27, 2019  (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the location of its 2019 Annual Meeting of Stockholders, to be held on Sept. 5, 2019, at 8:00 a.m. ET, has been moved to The Study at University City, Banquet Salon, located at 20 S. 33rd Street, Philadelphia, PA 19104. The original date and time of the meeting have not changed.

Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

Roche  and Spark Therapeutics  announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Britain continue.

Roche, Spark extend $4.3 billion takeover again, this time to September 3

Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for

AbbVie

Allergan

Bristol-Myers

Celgene

Eli Lilly

Pfizer

Vertex Pharmaceuticals

Biotech companies exploded with "megadeals" in the first half of 2019 as pharmaceutical companies Bristol-Myers Squibb and AbbVie announced acquisitions worth a combined $137 billion.
The post Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019 appeared first on Investor's Business Daily.

Megadeals Enter Biotech Realm — And 3 Other Trends To Watch In 2019

Swiss drugmaker Roche  has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction and expects it to close this year.

Roche, Spark push back takeover deadline in $4.3 billion deal

Alexion Pharma

Novelion Therapeutics

Novartis

Spectrum Pharma

The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.

The 5 Most Expensive Drugs In US: What You Should Know

Gene therapy player Uniqure could head to the auction block, an analyst said Monday as shares of the biotech company popped. He also said Roche's plan to buy Spark Therapeutics could falter.

News for Spark Therapeutics Stock (ONCE)